In this week’s reconciliation markup, Democrats included a change to the Orphan Drug Tax Credit, which would negatively impact research on rare diseases affecting millions of Americans.
ICYMI: It was a busy week in the House with several committees marking up the Senate’s $3.5 trillion budget reconciliation package. (Here’s our readout, including news on drug price controls and the sustainable aviation fuel tax credit.)
But there was an unwelcome surprise: Section 138141 (page 609), which would make drug manufacturers ineligible to collect the Orphan Drug Tax Credit “if the drug had previously been approved by the Food and Drug Administration for a separate indication,” explains STAT News.
“The ODTC can help to offset the cost of developing and testing orphan therapies as they move through the clinical trial process,”explains the National Organization for Rare Disorders (NORD). “This longstanding incentive is particularly important for the many smaller companies focused exclusively on rare diseases.”
There are more than 7,000 known rare or “orphan” diseases,which combined affect 25-30 million Americans. Sadly, 95% have no treatment or cure—and if the provision is passed, R&D will be disincentivized further.
Before the Credit, there were only a handful of treatments for rare disease patients. Now there are hundreds being developed. Like for cystic fibrosis. The first treatment helped less than 1,000 patients. Today, 90% of CF patients have a life-changing therapy. If this provision were in place, thousands of those patients may not have a treatment option.
Masters’ Message: The idea of taking away the Orphan Drug Tax Credit is certainly no surprise. What is a complete surprise is that Congress would consider a move to destroy research into cures for vulnerable populations afflicted by rare diseases such as sickle cell and cystic fibrosis. We will be aggressively fighting back on behalf of patients in the rare disease community—just because their numbers are not huge doesn’t mean their suffering is any less real. It is shocking some Members of Congress would put those patients’ cures at risk. – Rich Masters, BIO’s Chief Public Affairs and Advocacy Officer
Read: Marking Rare Disease Day 2021
More Health Care News:
The San Diego Union-Tribune (Opinion): Antibiotic-resistant superbugs are a ticking time bomb in global healthcare
The PASTEUR Act and the DISARM Act could help, write BIO President & CEO Dr. Michelle McMurry-Heath and Dr. Andrew Tomaras, Chief Scientific Officer at Forge Therapeutics.
RealClearHealth (Opinion): White House plan on healthcare reform: mostly brickbats, some bouquets
“That healthcare package released by the White House has some good ideas and some dangerous ones,” including federal price negotiations, drug importation, and a federal board to determine “value,” says former FDA Associate Commissioner Peter J. Pitts, President of the Center for Medicine in the Public Interest and Visiting Professor at the University of Paris School of Medicine.
